OCUL · Ocular Therapeutix, Inc
$11.07
-0.02 (-0.18%)
At close · Aug 21
Market Cap
$2.43B
Shares
219.62M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$11.09
Open$11.53
Day$11.07–11.62
52W close$6.88–16.11
Avg vol 30d2.5M
Short int26.7M · 12.2% float · 13.5d
Short vol64%
Last earningsAug 3, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 3
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 3, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+11%
above
Price vs 50-day avg
+17%
above
RSI (14)
66
neutral
MACD trend
Positive
52-week position
46%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+29%
trailing
6-month return
+24%
trailing
YTD return
−9%
this year
Relative strength
+13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow
Distributing
-5% holders QoQ · +34 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
12.17% of float · ▼ -1.1% MoM · 13.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
260 holders — mid 3-yr range
Squeeze score
88
high risk · 0–100
Fundamentals
Revenue growth
+3%
Y/Y
EPS growth
−16%
Y/Y
Free cash flow
$-216.9M
Balance sheet
$712.1M
net cash
Quant / Vol
risk profile
Volatility
71%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
4.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2023
Net product revenue for DEXTENZA
· full year 2023
$55M – $60M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+11%
Bullish
Price vs 50-day avg
+17%
Bullish
RSI (14)
66
Neutral
MACD trend
Positive
Bullish
52-week position
46%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow
Distributing
-5% holders QoQ · +34 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
12.17% of float · ▼ -1.1% MoM · 13.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
260 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $7
Now $11 · 46%
Range high $16
vs 200-day avg +11%
vs 50-day avg +17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross proceeds from September 2025 equity offering | $475M | September 2025 | — |
| Net proceeds from equity offering | $445.6M | September 2025 | — |
| SOL-R Phase 3 randomized subjects | 631 | as of December 2025 | — |
| SOL-R Phase 3 subject target | 555 | as of December 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OCUL
this stock
Ocular Therapeutix, Inc
|
$2.43B | -8.6% | +3.5% | — | 12.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
ARGX
Argenx SE
|
$64.56B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OCUL | +9.8% | +28.7% | +24.1% | +35.7% | -8.7% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +11.8% | +25.3% | +12.9% | +33.7% | -20.5% |
Key facts
CIK
1393434
CUSIP
67576A100
13F (30d)
235 filings
232 filers
Visit website
Investor relations